Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hikma PharmaceuticalsHKMPF 89 Earnings per Share (Diluted) is $1.76 as of Jun. 2026. GuruFocus rates HKMPF with a GF Score™ of 89/100 and a GF Value™ of $28.53 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 786 Drug Manufacturers companies, Hikma Pharmaceuticals ranks worse than 58.27% on this metric.
During the past 12 months, Hikma Pharmaceuticals's average EPS without NRIGrowth Rate was 5.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 4.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 5.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 7.20% per year.
During the past 13 years, Hikma Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 59.40% per year. The lowest was -6.50% per year. And the median was 10.90% per year.
Hikma Pharmaceuticals (OTCPK:HKMPF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Hikma Pharmaceuticals Earnings per Share (Diluted) Related Terms
Hikma Pharmaceuticals Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals Earnings per Share (Diluted) Chart
HKMPF vs ZTS, UTHR: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's PE Ratio distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's PE Ratio falls into.
Hikma Pharmaceuticals Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Hikma Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $1.76 mean?
Hikma Pharmaceuticals (HKMPF) has a Earnings per Share (Diluted) of $1.76 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Hikma Pharmaceuticals and its competitors. According to the industry distribution chart, Hikma Pharmaceuticals ranks #458 out of 786 companies in the Drug Manufacturers industry, placing it in the top 58.3%.
Is Hikma Pharmaceuticals' Earnings per Share (Diluted) too high?
Hikma Pharmaceuticals' current Earnings per Share (Diluted) is $1.76. The Drug Manufacturers industry median Earnings per Share (Diluted) is 9.85. Hikma Pharmaceuticals' value of $1.76 is 82.1% below this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #458 out of 786 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hikma Pharmaceuticals has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Earnings per Share (Diluted) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #458 out of 786 companies for Earnings per Share (Diluted). This places Hikma Pharmaceuticals in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.85. Hikma Pharmaceuticals' value of $1.76 is 82.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.85, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Earnings per Share (Diluted) of $1.76 is 82.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Earnings per Share (Diluted) is $1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.53, compared to a current price of $22.19 — trading 22.2% below its estimated fair value. The current Earnings per Share (Diluted) is $1.76 and 82.1% below the Drug Manufacturers industry median of 9.85. Hikma Pharmaceuticals' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Earnings per Share (Diluted) is $1.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $22.19 is trading 22.2% below its estimated GF Value™ of $28.53.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Earnings per Share (Diluted): $1.76
GF Value™: $28.53 vs. price of $22.19 (22.2% below fair value)
Industry Position: 82.1% below the Drug Manufacturers median (#458 of 786)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
89GF Score
Get the complete analysis for HKMPF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
